<DOC>
	<DOC>NCT00445458</DOC>
	<brief_summary>The purpose of this study is to learn whether it is safe and effective to administer HKI-272 (neratinib) in combination with paclitaxel in patients with breast cancer.</brief_summary>
	<brief_title>A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criteria for both parts of clinical trial: Good performance status Normal ejection fraction Adequate cardiac, kidney, and liver function Adequate blood counts At least one measurable target lesion Negative pregnancy test for female subjects Inclusion Criteria for Part 1 Only: Pathologically confirmed solid tumor not curable with available standard therapy Inclusion Criteria for Part 2 Only: Pathologically confirmed breast cancer HER2 positive tumor Prior treatment with Herceptin Exclusion criteria for both parts of clinical trial: Major surgery, radiotherapy, chemotherapy or investigational agents within two weeks of treatment day 1 Subjects with bone or skin as the only site of disease Active central nervous system metastases Significant cardiac disease or dysfunction Significant gastrointestinal disorder Inability or unwillingness to swallow HKI272 capsules Prior exposure to HKI272 or other HER2 targeted agents, except trastuzumab (Part 2 only). Prior lapatinib is permitted in arm B of part 2. Treatment with a taxane within 3 months of treatment day 1 Grade 2 or greater motor or sensory neuropathy Pregnant or breast feeding women Known hypersensitivity to paclitaxel or Cremophor EL Prior treatment with anthracyclines with cumulative dose of &gt;400 mg/m^2 Any other cancer within 5 years with the exception of contralateral breast cancer, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin Exclusion Criteria for Part 2 Only: More than 1 (arm A) or 3 (arm B) prior cytotoxic chemotherapy regimen for metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>HKI-272</keyword>
	<keyword>neratinib</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>breast cancer</keyword>
</DOC>